SNDX - Company ID 0001395937
The table below shows Syndax Pharmaceuticals Inc's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $64.86M | $45.87M | $37.96M | $20.04M | $12.50M | $3.50M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $58.84M | $56.28M | $62.23M | $61.64M | $70.97M | $48.66M |
Syndax Pharmaceuticals Inc reported annual revenue of $172.35M for fiscal year 2025. That is up 627.8% from $23.68M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.22M (FY 2016) to $172.35M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $37.59M |
| $44.92M |
| $43.80M |
| $41.03M |
| $31.11M |
| $29.06M |
| Operating income | -$34.20M | -$57.43M | -$69.35M | -$83.76M | -$89.58M | -$74.22M |
| Income tax | $0.00 | - | - | $0.00 | - | - |
| Net income | -$42.67M | -$60.72M | -$71.85M | -$84.85M | -$84.13M | -$68.06M |
| EPS (diluted) | -$0.48 | -$0.70 | -$0.83 | -$0.98 | -$0.98 | -$0.80 |